BRIEF-Ayrton Capital Reports 9.99% Passive Stake In Lucid Diagnostics
Reuters · 1h ago
Lucid Diagnostics (LUCD) Gets a Buy from BTIG
TipRanks · 03/16 09:45
Lucid Diagnostics Earnings Perspective: Return On Capital Employed
Benzinga · 03/15 14:48
Needham Reaffirms Their Buy Rating on Lucid Diagnostics (LUCD)
TipRanks · 03/14 20:25
Needham Maintains Buy on Lucid Diagnostics, Lowers Price Target to $2.6
Benzinga · 03/14 18:17
BRIEF-Lucid Diagnostics Says Qtrly Loss Per Share $0.47
Reuters · 03/14 17:39
Lucid Diagnostics Non-GAAP EPS of -$0.15 beats by $0.17, revenue of $0.11M misses by $0.27M
Seeking Alpha · 03/14 06:15
Lucid Diagnostics Q4 EPS $(0.29) Beats $(0.38) Estimate, Sales $112.00K Miss $340.00K Estimate
Benzinga · 03/14 04:56
BRIEF-Lucid Diagnostics Provides Business Update And Q4 And Full Year 2022 Financial Results
Reuters · 03/13 22:27
A Preview Of Lucid Diagnostics's Earnings
Benzinga · 03/13 16:01
FOCUS-Elon Musk's challenge: Stay ahead of the competition
Reuters · 02/24 06:00
Why PAVmed Shares Are Falling Today
Benzinga · 01/18 19:18
TC Biopharm, G Medical top healthcare gainers; Lucid, Hyperfine among losers
Seeking Alpha · 01/18 15:00
PAVmed, Lucid Diagnostics Pause Some Development Programs, Announce Layoffs
Benzinga · 01/18 11:24
Needham Keeps Their Buy Rating on Lucid Diagnostics (LUCD)
TipRanks · 01/18 11:05
PAVmed, its units Lucid Diagnostics, Veris Health implement strategic changes, layoffs
Seeking Alpha · 01/17 21:40
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 01/17 21:31
PAVmed, Subsidiaries to Cut 20% of Jobs, Streamline Product Portfolio to Reduce Quarterly Cash Burn
PAVmed, Subsidiaries to Cut 20% of Jobs, Streamline Product Portfolio to Reduce Quarterly Cash Burn
MT Newswires · 01/17 16:46
Catalyst watch: Eyes on Virgin Galactic, Monster Beverage, Procter & Gamble and Netflix
Seeking Alpha · 01/13 20:00
PAVmed And Lucid Diagnostics To Provide Strategic Business Update
Benzinga · 01/11 13:02
Webull provides a variety of real-time LUCD stock news. You can receive the latest news about Lucid Diagnostics Inc. through multiple platforms. This information may help you make smarter investment decisions.
About LUCD
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). Its products include EsoCheck and EsoGuard. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in an office procedure. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. EsoGuard is a bisulfite-converted next generation sequencing (NGS) deoxyribonucleic acid (DNA) assay performed on surface esophageal cells collected with EsoCheck. It is also developing EsoCure, which is an esophageal ablation device to treat dysplastic barretts esophagus (BE) before it can progress to EAC.